Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants
Study Details
Study Description
Brief Summary
The purpose of this study is to describe respiratory syncytial virus (RSV) hospitalization rates and to begin to address the utilization of outpatient resources for RSV medically-attended lower respiratory tract infections (MALRI) in 32-35 week gestational age (GA) premature infants who are less than 6 months of age and do not receive treatment.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
The goals of this study are:
-
To estimate the incidence of hospitalization attributable to RSV within 150 days from enrollment in premature infants who are:
-
32-35 weeks GA
-
less than 6 months of age at the start of the RSV season
-
not receiving palivizumab prophylaxis and not recommended to receive palivizumab according to the AAP guidelines
-
To estimate the incidence rate of hospitalization attributable to RSV in the other relevant study populations and time periods (e.g., Cohort 2, Cohorts 1 and 2 combined, and subgroups based on chronological age at the start of the RSV season, GA, etc. within 150 days from enrollment and other time periods based on RSV activity, etc.)
-
To estimate the incidence of RSV-associated MALRI in the study populations
-
To characterize the incidence and type of clinical interventions for MALRI in the study populations
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
1 Premature Infants (32-35 wks. GA) who are less than six months of age at start of RSV season and followed until May of the following year. |
|
2 Premature newborns (32-35 wks. GA) who are born during the current RSV season and discharged from the hospital after 01 Dec and followed until May of the next year. |
Outcome Measures
Primary Outcome Measures
- Estimate the incidence of hospitalization attributable to RSV within 150 days from enrollment in premature infants [150 days from enrollment]
Secondary Outcome Measures
- Estimate the incidence rate of hospitalization attributable to RSV in the other relevant study populations [150 days after enrollment]
- Estimate the incidence rate of MALRI attributable to RSV in the study populations; [during follow up]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Parent/legal guardian able to understand and provide written informed consent
-
Male or female infants born at 32-35 weeks GA. GA will be determined according to available medical records.
-
Clinically stable, in the opinion of the investigator
-
Ability and willingness of the subject's parent/legal guardian to complete all protocol mandated follow-up telephone calls, visits and procedures
-
Not more than one of the following American Academy of Pediatrics (AAP)-defined risk factors:
-
Childcare attendance
-
School-aged siblings in the home
-
Exposure to environmental air pollutants (not including passive exposure to tobacco smoke)
-
Congenital abnormalities of the airways
-
Severe neuromuscular disease, as determined by the investigator
- Subject must meet the criteria listed below for either Cohort 1 or Cohort 2:
Cohort 1
-
Date of enrollment between 01/Oct and 15/Dec
-
Chronological age of < 6 months (i.e., has not yet reached 6-month birthday) at the traditional start of the local RSV season (as used to determine eligibility for RSV prophylaxis)
Cohort 2
-
Date of enrollment between 16/Dec and 15/Feb
-
Born during the current RSV season and discharged from the hospital nursery after 01/Dec
Exclusion Criteria:
-
Previous (within 90 days of enrollment) or concurrent treatment with palivizumab or RSV-IGIV or IVIG
-
Hospitalization at the time of enrollment (unless discharge is anticipated within 10 days)
-
Two or more AAP-defined risk factors as listed under Inclusion Criteria
-
Participation in trials of investigational RSV prophylaxis or therapeutic agents
-
Confirmed prior or current RSV infection (a child with current signs/symptoms of respiratory infection must have negative RSV testing)
-
Diagnosis of chronic lung disease (CLD) of prematurity (formerly referred to as bronchopulmonary dysplasia [BPD])
-
Diagnosis of hemodynamically significant congenital heart disease (CHD), defined as requiring medication or supplemental oxygen for their CHD
-
Known immunodeficiency
-
Life expectancy of < 6 months
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University of Alabama at Birmingham | Birmingham | Alabama | United States | 35233 |
2 | Central Arkansas Pediatric Clinic, P.A. | Benton | Arkansas | United States | 72019 |
3 | The Children's Clinic of Jonesboro, P.A. | Jonesboro | Arkansas | United States | 72401 |
4 | Arkansas Children's Hospital Research Institute | Little Rock | Arkansas | United States | 72205 |
5 | Arkansas Pediatric Clinic | Little Rock | Arkansas | United States | 72205 |
6 | Little Rock Children's Clinic | Little Rock | Arkansas | United States | 72205 |
7 | Miller Children's Hospital | Long Beach | California | United States | 90806 |
8 | Children's Hospital of Oakland | Oakland | California | United States | 94609 |
9 | Children's Hospital of Orange County | Orange | California | United States | 92868 |
10 | Children's Hospital | Denver | Colorado | United States | 82018 |
11 | Pediatric Pulmonology, LLC | Stamford | Connecticut | United States | 06902 |
12 | Shands Hospital at the University of Florida | Gainesville | Florida | United States | 32610 |
13 | University of Miami Medical Center | Miami | Florida | United States | 33136 |
14 | University of South Florida Pediatrics Ambulatory Care Center | Tampa | Florida | United States | 33136 |
15 | Georgia Pediatric Pulmonology Associates | Atlanta | Georgia | United States | 30342 |
16 | Kapiolani Medical Center | Honolulu | Hawaii | United States | 96826 |
17 | University of Illinois at Chicago | Chicago | Illinois | United States | 60612 |
18 | Children's Memorial Hospital | Chicago | Illinois | United States | 60614 |
19 | Memorial Hospital of South Bend | South Bend | Indiana | United States | 46601 |
20 | University of Maryland, School of Medicine | Baltimore | Maryland | United States | 21201 |
21 | Tufts-New England Medical Center | Boston | Massachusetts | United States | 02111 |
22 | Boston Medical Center | Boston | Massachusetts | United States | 02118 |
23 | Children's Healthcare D.B.A. Hospitals & Clinics | St. Paul | Minnesota | United States | 55102 |
24 | Pediatrix Medical Group, St. John's Mercy Medical Center | St. Louis | Missouri | United States | 63141 |
25 | Midwest Children's Health Research Institute, LLC | Lincoln | Nebraska | United States | 68505 |
26 | Creighton University Medical Center | Omaha | Nebraska | United States | 68198 |
27 | Albany Medical Center | Albany | New York | United States | 12208 |
28 | Bronx-Lebanon Hospital Center | Bronx | New York | United States | 10457 |
29 | Jacobi Medical Center | Bronx | New York | United States | 10461 |
30 | Montefiore Medical Center | Bronx | New York | United States | 10467 |
31 | Winthrop University Hospital | Mineola | New York | United States | 11501 |
32 | University of Rochester Medical Center | Rochester | New York | United States | 14624 |
33 | University Hospital, State University of New York at Stony Brook | Stony Brook | New York | United States | 11794 |
34 | Crouse Hospital NICU | Syracuse | New York | United States | 13210 |
35 | Carolinas Medical Center | Charlotte | North Carolina | United States | 28203 |
36 | Duke University Medical Center | Durham | North Carolina | United States | 27710 |
37 | Raleigh Pediatric Associates | Gardner | North Carolina | United States | 27529 |
38 | Raleigh Pediatric Associates | Raleigh | North Carolina | United States | 27615 |
39 | Children's Hospital Medical Center of Akron | Akron | Ohio | United States | 44308 |
40 | Beehly Medical Park Women's and Children's Pavilion | Boardman | Ohio | United States | 44512 |
41 | University of Cincinnati College of Medicine | Cincinnati | Ohio | United States | 45267 |
42 | Metro Health Medical Center | Cleveland | Ohio | United States | 44109 |
43 | Children's Medical Center | Dayton | Ohio | United States | 45404 |
44 | Pediatric Associates of Dayton, Inc. | Kettering | Ohio | United States | 45429 |
45 | St. Vincent Medical Center | Toledo | Ohio | United States | 43608 |
46 | Oregon Health & Science University | Portland | Oregon | United States | 97239 |
47 | St. Luke's Hospital | Bethlehem | Pennsylvania | United States | 18015 |
48 | Geisinger Medical Center - JW Children's Hospital | Danville | Pennsylvania | United States | 17822 |
49 | Pennsylvania Hospital | Philadelphia | Pennsylvania | United States | 19017 |
50 | Children's Hospital of Pittsburgh | Pittsburgh | Pennsylvania | United States | 15213 |
51 | Rhode Island Hospital | Providence | Rhode Island | United States | 02903 |
52 | Driscoll Children's Hospital | Corpus Christi | Texas | United States | 78414 |
53 | University of Texas Southwestern Medical Center | Dallas | Texas | United States | 75390 |
54 | University of Texas Houston Medical Center | Houston | Texas | United States | 77030 |
55 | VCU Medical Center, Children's Pavillion | Richmond | Virginia | United States | 23298 |
56 | University Physicians Internal Medicine | Huntington | West Virginia | United States | 25701 |
57 | West Virginia University | Morgantown | West Virginia | United States | 26506 |
58 | Children's Hospital Waukesha Memorial | Waukesha | Wisconsin | United States | 53118 |
59 | Children's Corporate Center | Wauwatosa | Wisconsin | United States | 53226 |
Sponsors and Collaborators
- MedImmune LLC
Investigators
- Study Director: Frank Malinoski, M.D., PhD, MedImmune LLC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MI-MA140